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Objectives: Natriuretic peptides have been shown to improve renal blood flow and stimulate natriuresis. In a re-
cent retrospective trial, we documented that prophylactic use of nesiritide was associated with a 66% reduction in
the odds for dialysis or in-hospital mortality at 21 days in patients undergoing high-risk cardiac surgery; therefore,
we designed a prospective trial.
Methods: This prospective, randomized, clinical trial included 94 patients undergoing high-risk cardiac surgery
comparing a 5-day course of continuous nesiritide (at a dose of 0.01 mg $ kg1 $ min1 started before surgery)
versus placebo. The primary end point was dialysis and/or all-cause mortality within 21 days; secondary end
points were incidence of acute kidney injury, renal function, and length of stay.
Results: Nesiritide did not reduce the primary end point of incidence of dialysis and/or all-cause mortality
through day 21 (6.6% vs 6.1%; P ¼ .914). Fewer patients receiving nesiritide had acute kidney injury (defined
as an absolute increase in serum creatinine 0.3 mg/dL from baseline or a percentage increase in serum creatinine
 50% from baseline within 48 hours) compared with controls (2.2% vs 22.4%; P ¼ .004), and mean serum
creatinine was lower in the immediate postoperative period in the nesiritide group (1.18  0.41 mg/dL vs 1.45
 0.74 mg/dL; P ¼ .028). However, no difference in length of stay was noted (nesiritide 20.73  3.05 days
vs control 21.26  4.03 days; P ¼ .917).
Conclusions: These results do not demonstrate a benefit for prophylactic use of nesiritide on the incidence of
dialysis and/or death in patients undergoing high-risk cardiac surgery. Although nesiritide may provide some re-
nal protection in the immediate postoperative period, no effect on length of stay was observed.P
MAcute kidney injury (AKI) is a major complication of the
more than 200,000 cardiovascular operations performed
on adult Americans annually.1 The incidence of AKI after
cardiac surgery is generally low (1%–2%)2 but is much
higher in patients with thoracic aortic aneurysm and car-
diac valve operations (AKI: 25%–40%; perioperative
mortality: 8%–10%).3,4 When thoracic aortic aneurysm
surgery is complicated by AKI requiring renal replacement
therapy (RRT), the mortality rate rises to 50%.5 There are
very few effective interventional studies in this group of
patients.
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renoprotection owing to their ability to cause renal vasodila-
tion, stimulation of natriuresis, and preservation of glomer-
ular filtration rate (GFR). However, the literature on the
effectiveness of natriuretic peptides in the prevention of
AKI remains controversial.6 In a large observational study
(n ¼ 940) to evaluate the clinical effectiveness of natriuretic
peptides in the prevention of AKI after cardiovascular
surgery, we7 demonstrated a 66% reduction in the odds
for dialysis or in-hospital mortality at 21 days in subjects
whose baseline serum creatinine (SCr) value was less than
1 mg/dL. Because this latter study was retrospective, we
proceeded with a prospective, double-blind study to evaluate
the effect of nesiritide on renal tissue injury, renal function,
and requirement for RRT and/or all-cause mortality in
patients undergoing high-risk cardiac surgery.
METHODS
The study is a prospective, double-blind, placebo-controlled, random-
ized clinical trial conducted by the nephrology and cardiovascular surgery
teams at Shands Hospital at the University of Florida in Gainesville. The
study was approved by the Western Institutional Review Board, registered
at the National Institutes of Health’sClinicalTrials.gov (NCT00110201)
Web site, and was funded by an investigator-proposed grant from Scios,
Inc.ardiovascular Surgery c Volume 138, Number 4 959
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MAbbreviations and Acronyms
AKI ¼ acute kidney injury
AKI0.3mg/dL ¼ absolute increase in serum creatinine
of more than or equal to 0.3 mg/dL
from baseline
AKI50% ¼ increase in serum creatinine of more
than or equal to 50% from
baseline within 48 hours
CI ¼ confidence interval
GFR ¼ glomerular filtration rate
MDRD ¼ Modification of Diet in Renal
Disease
OR ¼ odds ratio
RRT ¼ renal replacement therapy
SCr ¼ serum creatinine
Participants
Initially, patients undergoing surgery for thoracic aortic aneurysm who
were older than 18 years of age and had an SCr value greater than 1 mg/
dL but less than 2 mg/dL were deemed to be at high risk per review of
the literature2 and were eligible for the study. Because of low enrollment,
after the first 2 patients were enrolled the inclusion criteria were modified
to include patients with cardiac valve surgery, and the SCr criterion was re-
placed with estimated GFR (using the short version of the Modification of
Diet in Renal Disease [MDRD] GFR calculator) between 30 and 90 mL $
min1 $ 1.73 m21 to better reflect renal function. Patients with a history
of adverse reaction to nesiritide, organ transplant, preoperative intra-aortic
balloon pump, or symptomatic, acute decompensated congestive heart fail-
ure were excluded.
Study Protocol
Eligible patients were randomized according to race, gender, and diabe-
tes status to receive a 5-day course of continuous nesiritide (at a dose of 0.01
mg $ kg1 $min1) or an identical appearing placebo, starting in the operating
room immediately before the operation. Study drugs were titrated to a max-
imum of 0.03 mg $ kg1 $ min1 over a 4-hour period to maintain postoper-
ative urine output greater than 1 mL $ kg1 $ h1. Patients who did not
achieve target urine output after the maximum dose of study drug or placebo
could then receive 1 to 5 mg bumetanide bolus intravenously, followed by
bumetanide continuous infusion as required. All patients received routine
postoperative supportive care for their medical and surgical problems, in-
cluding care for AKI, optimization of fluid and nutritional status, inotropic
support, and adjustment of doses of medication as appropriate for patients
with renal dysfunction. The need for RRT was determined independently
by the patient’s treating nephrologists per current standard of care criterion,
which included blood urea nitrogen greater than 80 mg/dL, electrolyte or
acid-base disorders not responding to medical management, and diuretic un-
responsiveness with urine output less than 0.5 mg $ kg1 $ h1 and refractory
volume overload as defined by central venous pressures greater than 15 mm
Hg. Postoperative GFR was calculated using the MDRD GFR calculator
and is in accordance with previous published reports.8,9
Outcomes
The primary end point of the study was the incidence of dialysis and/or
all-cause mortality through day 21. The predetermined secondary end points
included the incidence of AKI, mean SCr, peak SCr, change from baseline
to peak SCr, peak blood urea nitrogen, end of hospital stay, or study day 21;
mean urine output per day by day 5; and length of hospital stay. AKI is de-960 The Journal of Thoracic and Cardiovascular Sufined as an absolute increase in SCr of more than or equal to 0.3 mg/dL from
baseline (AKI0.3mg/dL) or an increase in SCr of more than or equal to 50%
from baseline within 48 hours (AKI50%) after surgery in accordance with
the Acute Kidney Injury Network’s criteria.10 Post hoc analyses included
the percent change in postoperative GFR relative to baseline.
Sample Size and Randomization
The sample size was calculated on the basis of a retrospective study that
examined the University of Florida experience with nesiritide in patients un-
dergoing cardiac surgery7 and had an 80% power to declare efficacy or harm.
The study plan was based on rates of composite end points of 20% (placebo)
versus 5% (nesiritide). The targeted population for the trial had an observed
odds ratio (OR) of 0.21, similar to that reported in the retrospective study (OR
0.19).7 Up to a total of 164 (was 124) patients undergoing thoracic aortic an-
eurysm surgerywere to be enrolled and randomized to receive nesiritide or an
identical appearing placebo drug. Randomization was performed by the In-
vestigational Drug Program housed in Pharmacy at the Shands Hospital.
The studywasconducted as a 2-stagegroup sequential designwith 92patients
assigned to stage I (46patients per arm) and72patients assigned to stage II (36
additional patients per arm). The following inferential rule was used: (1) If the
Z-test for proportions (pooled standard deviation) in stage I falls above 2.28 in
absolute value, halt the study anddeclare efficacy/harm. If this Z-test in stage I
falls below 1.08 in absolute value, halt the study and declare futility. If the Z-
test in absolute value at stage I falls between 1.08 and 2.28, continue to stage
II. (2) If after stage II the Z-value (pooled standard deviation) exceeds 2.00 in
absolute value, declare efficacy/harm. Otherwise, declare no significant dif-
ference. If there is indeed no advantage for the drug in the true target popula-
tion, there is a 5% probability of falsely declaring efficacy or harm (type I
error). On the basis of a pilot study, the estimated incidence in the aneu-
rysm/valve stratum in the cohort study was 4.4% for nesiritide versus
18.7% for no nesiritide. If the true failure rates are 5% for the drug and
20% for the placebo, the study has an 80% power to declare efficacy. Other
end points will be studied using the Z-test for proportions or t tests for quan-
titative end points, but the study is powered strictly on the basis of the primary
combined end point. This design is minimax in the sense that no 2-stage de-
sign with 80% power at P< .05 has a smaller maximum expected sample
size. Theworst-case scenario is an average sample size of 126 patients, which
occurs when the actual target population difference is 11%, rather than 0%
(null hypothesis) or 15% (alternate hypothesis). A single stage study would
have required 146 patients. The primary analysis is by intent-to-treat.
Patients were enrolled from the cardiothoracic surgery service at the Uni-
versity of Florida. Informed consent was obtained for all patients. Random
allocation sequences were generated by block stratification by the institu-
tional investigational drug services and concealed until the study was com-
pleted. The study participants, physicians, nurses, and data analysis teams
were blinded to group assignment.
Statistical Methods
Demographic characteristics, perioperative variables, and outcomes
were compared by univariate and multivariate analyses. The change from
baseline to postoperative peak SCr was compared by an analysis of covari-
ance model, with treatment group as qualitative factor and baseline SCr
value as covariate, as well as using nonparametric tests. Data are presented
as mean  standard error of mean. Univariate comparisons of the presence
of risk factors were computed by c2 and unpaired t tests for categorical and
continuous variables, respectively.
Study Design, Data Safety, Analysis, and Manuscript
Preparation
The study conception, design, execution, data collection, analysis, and
manuscript preparation were performed in their entirety and independently
by the investigators. The Data Safety Monitoring Board provided appropri-
ate oversight and monitoring of the conduct of the clinical trial to ensure the
safety of participants and the validity and integrity of the data.rgery c October 2009
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Excluded (n=412)
Not meeting inclusion criteria (n=309)
Refusing to participate (n=98)
Other (n=5)
Randomized (n=103)
Allocated to intervention (n=49)
Received intervention (n=45)
Did not receive intervention (n=4)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analyzed (n=45)
Excluded from analysis (n=0)
Allocated to intervention (n=54)
Received intervention (n=49)
Did not receive intervention (n=5)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analyzed (n=49)
Excluded from analysis (n=0)
A
n
a
l
y
s
i
s
F
o
l
l
o
w
-
u
p
A
l
l
o
c
a
t
i
o
n
E
n
r
o
l
l
m
e
n
t
FIGURE 1. Flow of participants.P
MRESULTS
In accordance with the a priori determination, the study
was stopped after completion of stage I inasmuch as the Z-
test was below 1.08 in absolute value. Importantly, the pri-
mary event rate was low in both groups (nesiritide 3/45
[6.6%] vs control 3/49 [6.1%]), and it was determined
that statistical significance for a definitive result could not
be achieved during the second stage of the study.
Patient Enrollment
The number of subjects screened, enrolled, and dropped
out are shown in Figure 1. One hundred three patients com-
pleted enrollment but 9 withdrew consent. The remaining 94
patients constituted the study cohort.
Baseline Characteristics
Mean age of the study population was 65.1  12 years,
66% of the patients were male, and 92.5% were white.
Mean preoperative SCr was 1.17 0.29 mg/dL with a calcu-
lated MDRD GFR of 63.7 16.3.4 mL $min1 $ 1.73 m21;
and left ventricular ejection fraction was 49.4%  9.4% (n
¼ 89); comorbidities are presented in Table 1. There was no
significant difference between the 2 study groups with re-
spect to baseline demographic and clinical characteristics
(Table 1). Most patients (76.6%) underwent thoracic aortic
aneurysm surgery (ascending aortic and arch replacement,
57.5%; descending aortic replacement, 19.1%; valve
only, 23.4%). Differences in duration of surgery (nesiritide
424.66 16.26 minutes vs control 383.69 14.65 minutes;
P¼ .065), duration of cardiopulmonary bypass support (ne-
siritide 177.14  11.42 minutes vs control 158.41  9.29
minutes; P ¼ .207), and aortic crossclamp time (nesiritide
109.70  7.97 minutes vs control 106.66  7.02 minutes;
P ¼ .776) were not significant between the groups. Statisti-The Journal of Thoracic and Ccally significant differences were also not observed with re-
gard to the number of patients who underwent circulatory
arrest (nesiritide 53.3% vs control 42.9%; P ¼ .302; circu-
latory arrest time: nesiritide 20.77  2.90 minutes vs 14.90
 2.16 minutes; P¼ .113), thoractomy (nesiritide 31.1% vs
control 30.6%; P ¼ 1.000), and midline sternotomy (nesiri-
tide 68.9% vs control 69.4%; P ¼ 1.000) between the
groups.
Primary Outcome
There was no statistically significant difference between
the groups with regard to the incidence of dialysis and/or
all-cause mortality through day 21 (nesiritide 3/45 [6.6%];
control 3/49 [6.1%]; P ¼ .914) (Figure 2). In the nesiritide
group, 1 patient died on the second postoperative day of
complications of cardiovascular surgery unrelated to the
study drug (as assessed by the Data Safety Monitoring
Board) and 2 patients required continuous RRT. In the con-
trol group, 2 patients required hemodialysis and 1 patient re-
ceived treatment with continuous RRT. RRT was indicated
in the nesiritide group primarily for volume overload and de-
creased urine output (preceding 24-hour urine output: nesiri-
tide 1168.33  1050.44 mL vs control 4228.66  502.93
mL in patients who underwent dialysis; P ¼ .020), whereas
the indication in the control group was primarily for worsen-
ing renal function (SCr: nesiritide 1.83  0.15 mg/dL vs
control 5.03  0.55 mg/dL [P ¼ .023] in the nesiritide and
control patients undergoing dialysis, respectively). Patient
demographics and clinical characteristics were otherwise
not statistically different between the groups.
Secondary Outcomes
AKI50% developed in fewer patients receiving nesiritide
than in the control group (nesiritide 2.2% [1/45] vs controlardiovascular Surgery c Volume 138, Number 4 961
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M22.4% [11/49]; P ¼ .004). Similar results were observed
when a different criterion for AKI was applied: AKI0.3mg/dL
developed in fewer patients receiving nesiritide than in the
control group (nesiritide 6.6% [3/45] vs control 28.5%
[14/49]: P ¼ .007, OR 5.6, 95% CI [CI] 1.4–21) (Figure 3).
The difference in AKI was observed in patients with SCr
greater than 1.2 mg/dL (nesiritide 7.1% [1/14] vs control
43.7% [7/16]; P ¼ .030, OR 10.1, 95% CI 1.11– 97) and
in those who underwent thoracic aortic aneurysm surgery
(nesiritide 2.7% [1/37] vs control 25.7% [9/35]; P ¼
.006, OR 12.4, 95% CI 1.4–104.5).
The 5-day cumulative urine output (nesiritide 8.6  7.3L
vs control 14.9 2.9L; P¼ .269) was not different between
groups. The frequency of administration of standard doses of
diuretics was also not different (nesiritide 1.11  0.21 vs
control 1.28  0.23); half of the study participants did not
receive any diuretics (nesiritide 23/45 vs control 24/49;
P¼ .807) in the first 5 postoperative days.
TABLE 1. Baseline patient characteristics
Variable
Nesiritide
(n ¼ 45)
Control
(n ¼ 49)
P
value
Demographics
Age (y) 64.1  13.31 65.91  10.76 .484
Sex (% male) 64.4 67.3 .820
Race (%)
White 88.9 96 .147
African American 8.9 2 .190
Other 2.2 2 1.000
Surgery type (%)
TAA 82.2 71.4 .235
Valves 17.8 28.6 .217
Comorbid conditions (%)
Hypertension 68.9 63.3 .666
CAD 33.3 40.8 .524
Previous CV surgery 26.6 32.6 .652
Diabetes 17.8 12.2 .566
CVA 13.3 4.4 .147
PVD 11.1 4.1 .254
Renal function
SCr (mg/dL) 1.16  0.29 1.18  0.30 .702
MDRD GFR (mL $min1 $
[1.73 m2]1)
64.4  16.73 63.12  17.07 .693
BUN (mg/dL) 22.17  14.35 19.80  8.16 .356
Cardiac function
LVEF (%) 48.56  1.29 50.27  1.52 .394
NYHA class I (%) 93.3 89.7 .339
Mean arterial
pressure (mm Hg)
89.31  12.74 92.94  13.22 .178
Cleveland Clinic
Scoring System
3.40  0.22 3.51  0.23 .735
TAA, Thoracic aortic aneurysm; CAD, coronary artery disease; CV, cardiovascular;
CVA, cerebrovascular accident; PVD, peripheral vascular disease; SCr, serum creati-
nine; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association.962 The Journal of Thoracic and Cardiovascular SurLength of hospital stay (nesiritide 20.73  3.05 days vs
control 21.26  4.03 days; P ¼ .917) was not significantly
different between the groups. However, in the subset of pa-
tients who did have AKI (n ¼ 17), those receiving nesiritide
had shortened hospital stay (nesiritide 22.28  4.20 days vs
control 33  20.51 days; P ¼ .017) compared with the con-
trol group.
Post Hoc Analyses
By post hoc analyses, fewer patients in the nesiritide
group sustained severe kidney injury (defined as a rise in
SCr of 1 mg/dL or more) compared with patients in the con-
trol group (nesiritide 1 vs control 11; P ¼ .004). Postopera-
tive GFR relative to baseline also increased in the nesiritide
group whereas it decreased in the control group (1.76% 
4.1% vs11.68% 4.21%; P¼ .026) (Figure 4.). The dif-
ferences were more pronounced when analyses were re-
stricted to patients with baseline GFR less than 45 mL $
min1 $ (1.73 m2)1 (2.24%  13.41% vs 33.17% 
8.03%; P ¼ .075; n ¼ 13). In patients with the largest
decrease in postoperative GFR (30%; n ¼ 21), the use
of nesiritide was associated with a statistically significant
decrease in the incidence of AKI50% (22.2% [2/9] vs
91.6% [11/12]; P ¼ .002).
Side Effects: Hypotension and Nesiritide
Nesiritide has been associated with hypotension, espe-
cially if given by bolus.6 In this trial, episodes of hypoten-
sion solely related to the administration of nesiritide were
not recognized, in part because of the frequent concomitant
requirement for vasopressors in many of the patients. How-
ever, the number of vasopressors administered was higher in
the nesiritide group (P¼ .023). Significant differences in ab-
solute change in mean arterial pressures between the groups
were not evident through day 5 (P ¼ .858, .359, .914, .492,
and .930, days 1–5, respectively). Usage of diuretics did not
differ among the groups.
FIGURE 2. Incidence of primary events.gery c October 2009
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MDISCUSSION
AKI is a serious complication of cardiovascular surgery
and is associated with markedly increased rates of mortality
and morbidity.11-13 The pathogenesis of postoperative AKI
is complex but is thought to be mediated by a reduction in
renal blood flow associated with persistent renal vasocon-
striction, mediated in part by the release of proinflammatory
and vasoconstrictive mediators.14 Although a variety of tri-
als with different renal vasodilators have been negative,15-18
there has been recent interest in the use of natriuretic pep-
tides owing to their ability to cause afferent renal vasodila-
tion, improve GFR, and antagonize the proinflammatory
effects of a variety of cytokines.19,20 Indeed, in a recent un-
controlled retrospective trial, our group7 reported a remark-
able 80% decrease in AKI in subjects undergoing aortic
aneurysm therapy that received nesiritide therapy. Other
groups have also reported a reduction in AKI using either
atrial natriuretic peptide or brain natriuretic peptide after car-
diovascular surgery.8,21,22 This led us to do a prospective,
double-blind, controlled trial to determine whether nesiritide
could provide renal protection in subjects undergoing car-
diovascular surgery.
The design of the study was based on selecting subjects at
high risk for the development of AKI. We therefore studied
subjects undergoing aortic aneurysm surgery and/or subjects
having valve replacement with or without coronary artery
bypass in whom higher rates of AKI (4%–16%) can be
predicted. Furthermore, we also identified subjects with
modest (GFR 30–90 mL $ min1 $ [1.73 m2]1) but not se-
vere chronic kidney disease, inasmuch as our retrospective
study suggested that this is the group most likely to benefit
FIGURE 3. Incidence of acute kidney injury (AKI) using different
definitions.The Journal of Thoracic and Cfrom nesiritide prophylaxis. Furthermore, inasmuch as a ne-
siritide bolus can induce hypotension (reviewed in reference
6), we opted to initiate nesiritide as a continuous infusion
(without bolus administration) for 5 days beginning immedi-
ately before surgery in the operating room. Although no hy-
potension attributable to nesiritide was noted, subjects
randomized to nesiritide were administered pressors more
frequently.
The major finding in this study was that the primary end
point, defined as dialysis or death, was not different between
groups. Importantly, there was no favorable effect of ran-
domization to nesiritide with regard to the incidence of dial-
ysis and/or all-cause mortality through day 21. One problem
was that fewer patients reached this end point (3 subjects per
group) than anticipated, and that indeed contributed to the
futility. This did not differ even when the data were analyzed
with a different criterion (need for dialysis defined as SCr 
4.5 mg/dL) that was used in a study that reported improved
dialysis-free survival with natriuretic peptides (nesiritide 4/
45 vs 4/49; P ¼ 1.00).21 It was of interest that AKI necessi-
tating RRT developed in all 3 control patients whereas the 2
nesiritide-treated subjects received RRT for clinical evi-
dence of volume overload. Nevertheless, these numbers
are too small to make any definitive statements related to po-
tential differences in reasons that patients achieved the pri-
mary outcome.
In terms of secondary end points, there was no difference
in hospital length of stay in either group. However, we did
observe some evidence for renoprotection as noted by re-
duced AKI in the nesiritide group versus the placebo group.
It is possible that this may represent the known effect of na-
triuretic peptides to cause renal vasodilation, and hence that
the effect on renal function simply reflects a transient hemo-
dynamic effect. Although this remains a possibility, the use
of other renal vasodilators, such as dopamine and fenoldo-
pam, was not associated with any benefit in renal function
in the acute postoperative period.16,17
FIGURE 4. Percent change in postoperative glomerular filtration rate
(GFR) compared with baseline.ardiovascular Surgery c Volume 138, Number 4 963
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MPost hoc analyses suggested that nesiritide may provide
greater renoprotection in subjects with baseline renal insuf-
ficiency (estimated GFR<45 mL $min1 $ [1.73 m2]1). Fu-
ture studies may be indicated to determine whether targeting
this specific population could result in different outcomes.
Until this is shown in multicenter randomized trials, we do
not recommend the routine use of nesiritide for the prophy-
laxis of patients undergoing cardiovascular surgery.
The investigators acknowledge the active support of DSMB
members Abraham Hartzema, PharmD, MSPH, PhD, Meenakshi
Devidas, PhD, Edward A. Ross, MD, Daniel F. Pauly, MD, PhD,
and study coordinators Allan Finlay, RN, Michelle Armstrong,
RN, Karissa Roberts, Mary Alice Dennis, RN, andMichelle Hunter
during the course of the study.
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